Is Zevra Therapeutics, Inc. (NASDAQ:ZVRA) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Zevra Therapeutics, Inc. at current levels.
MIPLYFFA is a real commercial drug in an underserved ultra-rare market, and the Street is treating Zevra like it still has to prove itself.
Where ZVRA is headed
By the back end of 2027, Zevra looks less like a hopeful rare-disease story and more like a small, profitable specialty pharma with three commercial drugs and a clinic-stage pipeline that could genuinely surprise. MIPLYFFA (arimoclomol) for Niemann-Pick Type C is the centerpiece. The US patient pool is tiny, somewhere around 300 identified patients on therapy by year-end, but at roughly $750k a year per patient the math gets interesting fast. Push penetration toward the diagnosed-but-untreated cohort and you get to a $200M+ run rate from MIPLYFFA alone, on a cost base that barely moves. That is the bridge from where Zevra is today (around $90M TTM revenue, already profitable on a GAAP basis with 86% gross margins) to a business doing $250-300M in revenue with operating margins north of 30%.
Read the full Compass Direction on ZVRA
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $10.03).
See the full ZVRA analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Zevra Therapeutics, Inc. (NASDAQ:ZVRA) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Zevra Therapeutics, Inc. at current levels. MIPLYFFA is a real commercial drug in an underserved ultra-rare market, and the Street is treating Zevra like it still has to prove itself.
What is ZVRA's Compass Score?
Zevra Therapeutics, Inc. scores 82/100 on Alexandria's Compass, placing it in the "True North" tier. Scores blend eight factors and update weekly.
What is the price target for ZVRA?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the ZVRA page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.